Abstract Despite the advent of novel targeted therapies with high overall response rates, chronic lymphocytic leukemia (CLL) is still largely incurable due to the development of resistance. The bone marrow microenvironment (BMME) plays an important role in the survival and drug resistance in CLL. BM stromal cells (BMSCs) are considered a key component of BMME. Our long-term goal is to gain further insights of BMSCs-CLL crosstalk influencing both survival and drug resistance in CLL. To understand the global biologic changes that occur in leukemic CLL cells when in contact with BMSCs, we assessed RNA-seq in paired CLL cells isolated from untreated blood and BM and in untreated patients’ CLL cells cultured alone or with BMSCs. CLL cells from blood/BM and cultured alone/with BMSCs were also examined by Immunoprecipitation (IP), Western blot (WB), untargeted metabolomics (LCMS+GCMS), and preclinical drug sensitivity assays. We detected only 13 upregulated genes that overlap between CLL cells from BM and cocultured with BMSCs (p<0.05, fold change >1.5). When we analyzed the expression of these 13 genes in CLL cells from a cohort of 162 untreated patients by RNA-seq, we found associations between 4 genes (PNP, C16orf54, MOB3A, CDK2AP2) and clinical outcomes including overall survival (OS), progression free survival (PFS), and time to first treatment (TTFT) [multivariable Cox proportional hazards models, p<0.05]. Of the 4 genes, purine nucleoside phosphorylase (PNP), an enzyme in the purine pathway, had the most significant association with OS, PFS, and TTFT. Metabolomic profiling indicated an increased level of purine pathway metabolites adenosine, adenine, inosine, and hypoxanthine in cocultured CLL cells. WB analysis showed variable baseline PNP protein expression with 2 cohorts: low /no (L) and high (H) PNP using CLL blood cells. An induction in PNP protein levels were noticed in CLL cells expressing only LPNP when cocultured. Given the association of HPNP with adverse clinical outcomes, we tested for L vs. HPNP cohorts drug sensitivity to known BTK inhibitors(is) or Bcl2is. Treatment of CLL cells from untreated patients with Bcl2is venetoclax, S55746, and LP-118 (Bcl2-Bclxli, Newave) showed increased sensitivity to the Bcl2/Bclxlis in HPNP but not in LPNP cells. In addition, BTKis showed no difference in drug sensitivity associated with CLL PNP levels. To explain this discrepancy, WB and IP analyses were conducted in L vs. HPNP leukemic cells for apoptotic profiles, where we found increased phosphorylated-Bcl2(S70) and an increased association of Bcl2 with Bax in LPNP-expressing CLL cells compared to HPNP. These findings support increased resistance to apoptosis afforded by inhibiting Bcl2 for LPNP vs. HPNP-expressing CLL cells. Our future goals are to continue to understand the prognostic significance of the 4 genes with adverse clinical outcomes and to investigate how best to exploit the peculiar, enhanced sensitivity to Bcl2/Bclxlis found in the HPNP CLL cells. Citation Format: Sutapa Sinha, Weiguo Han, Zhiquan Wang, Brianna M. Finke, Heather C. Darby, Kari G. Rabe, Susan L. Slager, Chantal E. McCabe, Daniel R. O'Brien, Sameer A. Parikh, Esteban Braggio, Yi Chen, Fenlai Tan, Stephen P. Anthony, Yu Chen, Bing Dai, Yue Shen, Neil E. Kay. CLL drug resistance- A multifaceted mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4423.
Abstract 7392: The effects of socioeconomic deprivation on the tumor microenvironment of bladder cancer
Abstract Background: Bladder cancer patients with lower socioeconomic status (SES) often present with more aggressive disease and face poor outcomes, likely due to complex interactions with risk factors linked to lower SES. However, little is known about the effect of low SES on bladder tumor biology at the molecular level. This study sought to characterize better the impact of low SES on the bladder tumor microenvironment. Methods: This is a retrospective analysis of 93 patients (63 male and 30 female) ranging from age 33 to 92 presenting to the University of Arizona Cancer Center with bladder cancer from 2016-2023. Each patient's neighborhood level of SES was scored using the Area Deprivation Index on a scale of 1-100, with 1 representing the highest SES and 100 the least. These patients were then split into tertile 1: 1-33 (T1: N=16), tertile 2: 34-67 (T2: N=43), and tertile 3: 68-100 (T3: N=34), and each patient’s tumor microenvironment and mutational landscape was characterized and compared utilizing NGS (592, NextSeq; WES, NovaSeq) and WTS Sequencing (NovaSeq) (Caris Life Sciences, Phoenix, AZ). Statistical significance was determined using chi-square and Mann-Whitney U (p<0.05). Results: Our study had no significant difference between age, sex, and race between the three tertiles. Hispanic ethnicity was significantly higher in T3 (26.5%) when compared to T2 (7%) and T1 (0%), p=0.013. The frequency of TMB-H (>10 mutations/megabase) was significantly lower in T3 (15.6%) when compared to T2 (51.2%, p=0.02) and T1 (50%, p=0.01). There was significantly less T cell CD8+ infiltration in tertile 3 (0.02%) when compared to T2 (0.43%, p=0.04) and T1 (0.37%, p=0.08), and less dendritic cell infiltration in T3 (0%) when compared to T2 (0.1%, p=0.13) and T1 (0.64%, p=0.008). T regulatory cells were lower in T3 (1.37%) compared to T2 (2.13%, p=0.09) and T3 (2.02%, p=0.24). IHC-PD-L1 and gene expression for immune checkpoint genes, MHC-Class I, and MHC-Class II did not vary significantly between tertiles. KMT2C-mt was highest in T2 (21.1%) compared to T1 (3.12%, p=0.03) and T3 (6.67%). There was no other significant differences in mutation prevalence between the three tertiles. Discussion: In our study, lower SES bladder cancer patients had a lower amount of CD8+ cells, dendritic cell infiltration, and a low frequency of TMB-H, indicating a lower level of adaptive immune response present in the tumor microenvironment. Lower levels of adaptive immune activity have been associated with more aggressive tumor behavior and worse outcomes in bladder cancer patients. These findings provide a partial explanation of the molecular mechanisms underlying the poor prognosis observed in low SES patients with bladder cancer. Larger-scale studies exploring the impact of SES on tumor biology are essential as they hold significant therapeutic and preventive implications. Citation Format: Tom Marco, Kenneth Barker, Jesse Ritter, Numaan Mahmood, Rishab Srivastava, Amith Rao, Isaac Zarif, Ricardo Estrada Mendizabal, Sachin Deshmukh, Edgar Tapia, Jose Guillen-Rodriguez, Juan Chipollini, Alejandro Recio-Boiles. The effects of socioeconomic deprivation on the tumor microenvironment of bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7392.
Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A
Abstract Introduction: Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast lesion characterized by stromal myofibroblast accumulation. While most women with PASH do not develop breast cancer, a subset eventually does, often in the same breast where PASH was originally diagnosed, even after surgical removal of the lesion. This pattern suggests the presence of a field effect, where alterations in the PASH microenvironment extend beyond the lesion itself, potentially influencing neighboring breast tissue. This study aims to identify specific fibroblasts within PASH-containing tissues that may create a microenvironment conducive to cancer initiation. Methods: We conducted a retrospective analysis of formalin-fixed, paraffin-embedded breast tissue samples from women diagnosed with PASH, comparing those who later developed breast cancer (cases) to those who remained cancer-free (controls). Using transcriptional profiling with NanoString IO360/BC360 panels, multiplex immunofluorescence (MxIF), and spatial transcriptomics via NanoString CosMX SMI, we investigated molecular and histopathological differences. We focused on the expression of fibroblast activation markers (ITGB1, PDGFRβ) and their spatial relationships with proliferating epithelial cells, as well as changes in extracellular matrix (ECM) composition and stiffness. Results: Transcriptional profiling revealed significant upregulation of proliferation-associated genes in epithelial cells from cases. MxIF showed higher Ki-67 levels in epithelial cells from cases, with proliferating cells forming clustered regions. Activated fibroblasts expressing ITGB1 and PDGFRβ were markedly increased in cases and were located closer to proliferating epithelial cells. Spatial transcriptomics uncovered gene expression changes in fibroblasts indicative of an activated phenotype, and in epithelial cells, consistent with responses to increased tissue stiffness and mechanotransduction signaling. Polarized light imaging with picrosirius red staining revealed enhanced collagen cross-linking and thick fibril formation in cases, indicating greater ECM stiffness. Conclusions: Our findings suggest that a subset of activated fibroblasts in benign breast tissue creates a pro-tumorigenic microenvironment through ECM remodeling and increased tissue stiffness, promoting epithelial proliferation and potentially driving cancer development. The spatial proximity of these fibroblasts to proliferating epithelial cells underscores their possible role in early carcinogenesis. This study introduces the novel concept of cancer-predisposing fibroblasts in benign breast tissue, providing new insights into microenvironmental changes that precede cancer and offering potential targets for early detection and intervention. Citation Format: Nicole Cruz-Reyes, Pria Westerman, Matilde Rossi, Camila Pacheco Erak, Melody Stallings Mann, Bryan McCauley, Robert Vierkant, Stacey Winham, Mark Sherman, Amy Degnim, Derek Radisky. Activated fibroblasts in benign breast tissue are associated with subsequent breast cancer development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2083.
Abstract 4917: The association between MGUS and CHIP and their impact on multiple myeloma
Abstract Monoclonal gammopathy of undetermined significance (MGUS) is a precursor to multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP) is a precursor to either myeloid or lymphoid malignancy, depending on whether the mutation is in a gene associated with lymphoid (L-CHIP) or myeloid (M-CHIP) outcome. Little is known about the association between CHIP and MGUS and their combined effect on risk of MM. We examined this question within Mayo Clinic Biobank cohort of participants aged 50 years or older with no prior history of hematological malignancies. Using whole blood, individuals were screened for MGUS using a matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry assay. M-CHIP and L-CHIP were defined based on mutations in 56 genes associated with myeloid malignancies or mutations in 235 genes associated with lymphoid malignancies, respectively, using whole-exome-sequencing. Incident MM was identified using International Classification of Diseases (ICD) codes and confirmed via medical record review. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals for the association of CHIP and MGUS. Cox proportional hazards regression was used to estimate hazard ratios (HR), with time defined as date between blood sample and the first incident MM, date of death, or 12/31/2023. All models were adjusted for age and sex. Of the 16, 479 individuals (median age 65 years, 45% male) screened, 12.3% were positive for MGUS, 9.8% were positive for M-CHIP, and 1.5% were positive for L-CHIP. There was no evidence of an association between M-CHIP and MGUS (OR=0.97, 95% CI:0.83-1.12) nor L-CHIP and MGUS (OR=1.12, 95% CI:0.78-1.57), including with any MGUS isotype (IgA, IgG, or IgM; P-values>0.22). Next, we investigated the association of these precursors on risk of MM. Median follow-up was 11.7 years (range 0.1-15.1), and 46 individuals developed incident MM. Both MGUS (HR=29.7, 95% CI: 14.1-62.4) and L-CHIP (HR=4.1, 95% CI: 1.3-13.2) were significantly associated with incident MM, but not M-CHIP (HR-1.0, 95% CI: 0.4-2.5). Investigating the combined effect of MGUS and L-CHIP, we found those with MGUS alone had a 27.5-fold (95% CI: 13.0-58.2) increased risk of incident MM compared to those with no precursors. No individuals with L-CHIP only developed MM, but those with both L-CHIP and MGUS had a 129.4-fold (95% CI: 34.4-486.4) increased risk of incident MM. In the largest cohort with screened MGUS and CHIP, we found no evidence of an association between either definition of CHIP with MGUS. However, individuals with both L-CHIP and MGUS were at the highest risk of developing MM. Citation Format: Nicholas J. Boddicker, Cristine Allmer, Danelle H. Moonen, Aaron D. Norman, Angelica Macauda, Alyssa Clay-Gilmour, Janet E. Olson, Mrinal S. Patnaik, Vincent Rajkumar, Esteban Braggio, David L. Murray, Shaji Kumar, Susan L. Slager, Celine M. Vachon. The association between MGUS and CHIP and their impact on multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4917.
Abstract 5258: The immunomodulatory effects of daratumumab-based therapy on functional high-risk relapse/refractory multiple myeloma (fHRMM) patients enrolled in the MyDRUG trial
Abstract Background: The goal of this study is to evaluate the immunomodulatory effects of daratumumab-(anti-CD38)-based therapy on fHRMM patients enrolled in the MMRF sponsored MyDRUG umbrella clinical trial (NCT03732703) over the duration of therapy and to correlate immune changes with patient response. Methods: fHRMM who had received 1-3 prior therapies (exposed to at least one proteasome inhibitor and an IMiD) were given a combination of daratumumab (D), ixazomib (I), pomalidomide (P) and dexamethasone (d) (D-IPd) quadruplet therapy. Bone marrow (BM) aspirates were then collected from patients prior to therapy (BL), after 2 cycles (EOC2), after 4 cycles (EOC4) of the quadruplet therapy and at the end of treatment or disease progression (EOT). Immune and tumor fractions were enriched by CD138 selection. Here, CD138- bone marrow mononuclear cells were isolated and transcriptionally profiled by scRNAseq and scTCRseq. Results: Single-cell RNA and TCR profiles were generated from ∼90,000 cells across 41 samples from 16 subjects. scRNAseq identified CD3+ T cells, NK cells, classical and non-classical monocytes and B cells. CD8+ T cells were further resolved into their subsets including precursor (TPEX) and terminally exhausted T cells (TEX) within the bone marrow microenvironment. Within the CD8+ T cell compartment, an expansion of the effector memory (TEM) cell population was observed following 2-cycles of therapy (EOC2). However, this TEM expansion was not sustained at timepoint EOC4. Towards the end of therapy, enrichment of precursors to exhausted and terminal dysfunctional effector memory cells (TEMRA) was observed. Subjects with partial (PR), very good partial (VGPR) and complete (CR) best overall responses showed an initial increase in TEM cells followed by a slow expansion of TEX and TEMRA cells over time. Longitudinal tracking of T cell clonality showed preferential progressive expansion of TEMRA cells after the therapy. We mapped hyperexpanded (more than 16 copies) clonotypes, presumed to be tumor-reactive, to various CD8+ T cell subsets. These hyperexpanded clonotypes mapped to the TEMRA, TEX and TEM CD8+ T cells. Analysis of TCR repertoires clonality and diversity also demonstrated a reduced richness and increased clonality of CD8+ TCRs in responders. Conclusions: Paired single cell RNA and TCR sequencing of BM T cells from RRMM patients receiving D-IPd quadruplet therapy revealed a selective expansion of clonotypic CD8+ T cells with a clonal replacement of BM exhausted clonotypes by dysfunctional circulating CD8+ T cells in responders over time. Citation Format: Chaitanya R. Acharya, Darwin D'souza, Reyka Jayasinghe, Mark Hamilton, Zhihong Zhihong, Seunghee Kim-Schulze, Hearn J. Cho, Shaji Kumar, George Mulligan. The immunomodulatory effects of daratumumab-based therapy on functional high-risk relapse/refractory multiple myeloma (fHRMM) patients enrolled in the MyDRUG trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5258.
Severe Anaplasmosis with Multi-Organ Failure in a Patient with Splenectomy: A Case Report
Background: Anaplasma phagocytophilum is an emerging tick-borne zoonotic pathogen that typically causes mild infections, which are often successfully managed in outpatient settings. Immunosuppression associated with splenectomy is a well-documented risk factor for severe infections from pathogens such as Babesia microti and encapsulated bacteria. However, splenectomy has not previously been identified as a risk factor for severe anaplasmosis. Case Presentation: This report describes a rare case of severe anaplasmosis complicated by multiorgan failure in a patient who had undergone splenectomy several decades earlier. The clinical course was notable for pneumonia, acute respiratory distress syndrome, acute kidney injury, rhabdomyolysis, atrial fibrillation, and possible myocarditis. Despite the severity of the presentation, prompt initiation of doxycycline led to recovery, albeit with a significantly prolonged hospital stay. Conclusions: Patients with splenectomy might be more likely to develop a serious form of Anaplasmosis infection such as multiorgan failure. Clinicians in tick-borne endemic areas should be aware that non-specific symptoms can indicate anaplasmosis.
Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten
Background: Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy marked by increased left ventricular wall thickness, leading in some cases to left ventricular outflow tract (LVOT) obstruction, heart failure, and arrhythmias. Mavacamten, a selective allosteric inhibitor of cardiac myosin, has demonstrated benefits in improving hemodynamics and reducing LVOT obstruction. However, its impact on arrhythmic burden remains unclear, with reports of early atrial fibrillation (AF) risk contrasting with long-term reductions in arrhythmias. This study assesses the temporal patterns of Holter-detected arrhythmias in HCM patients treated with mavacamten. Methods: This retrospective study included HCM patients from three Mayo Clinic sites. Baseline demographic, clinical, and echocardiographic data were collected. Holter monitoring was performed at baseline, short-term (<6 months), and long-term (>6 months) follow-up. Arrhythmic events, including premature atrial contractions (PACs), premature ventricular contractions (PVCs), and supraventricular tachycardia (SVT), were analyzed using standardized rates per 24 h. Statistical comparisons utilized the Wilcoxon signed-rank test. Results: Twenty-seven patients (56% female, median age 66 years) were included. PACs, PVCs, and SVT duration transiently but not significantly increased at short-term follow-up but returned to baseline at long-term follow-up. No sustained or high-risk ventricular arrhythmias were observed. Conclusions: Mavacamten is associated with transient arrhythmic fluctuations early in treatment, followed by stabilization. These findings support its long-term electrophysiological safety and underscore the need for early rhythm monitoring. Further research should explore its role in arrhythmic risk stratification in HCM patients.
Abstract 6762: Baseline multiomics and chemotherapy efficacy in preclinical trials using patient-derived xenograft models of cholangiocarcinoma can reveal distinct signatures of chemotherapy response
Abstract Background: Cholangiocarcinoma (CCA) is a diverse type of cancer. For several years, platinum-based chemotherapy (Gemcitabine and Cisplatin) has been the standard treatment and serves as the foundation for current immunotherapy combinations. The typical response rates are generally between 20% and 30%. In this study, we present the results of preclinical efficacy trials conducted on CCA patient-derived xenograft (PDX) models, correlating them with the baseline multiomics profiling of these models to identify molecular characteristics linked to treatment response. Methods: Tumor samples from twenty-eight CCA PDX were used to isolate RNA and protein to be included in multiomics analysis (Phosphoproteomics, Proteomics, and Transcriptomics). A subset of PDX models were treated with various doses of Gemcitabine and Cisplatin. The Median Efficacy Index (MEI) was calculated as the ratio of the difference in median of delta in tumor volume at the last day of the study between the treatment and the control arms divided by the median of delta in tumor volume of the control at the last day of the treatment (positive= growth, negative=inhibition, and 0=no efficacy). A Hierarchical All-Against-All algorithm was utilized to compare multiomics features to the MEI and pathway analysis completed for identified molecular features. Pathway enrichment was calculated using the KEGG database, and random-forest variable selection chose the pathways most influential in predicting sensitivity or resistance. Results: After conducting preclinical efficacy trials, the 11 tested CCA PDX models were classified into sensitive, moderately sensitive, and resistant models based on the MEI on each treatment arm. The top up-regulated genes were identified for Gemcitabine response (SRPK2, GLK2, and RIOK2) and Cisplatin response (NTRK1, PRPF4B, and SRPK2). The top up-regulated genes related to Gemcitabine resistance were NTRK1, PIP5K1C, and CSNK2A2, while those related to Cisplatin resistance were SRPK1, PRPF4B, and CSNK2A1. Downregulation of the anti-folate resistance pathway is a strong predictor of gemcitabine sensitivity, and the lysine degradation pathway is a strong predictor of cisplatin sensitivity. Conclusion: Multiomics signatures of cholangiocarcinoma can forecast responses to standard chemotherapy in preclinical models. New markers of resistance to Gemcitabine and Cisplatin were discovered, linked to NTRK1, SRPK1, and SRPK2. These resistance profiles will be tested using suitable targeted therapies on the resistant CCA patient-derived xenograft (PDX) models. Citation Format: Amro M. Abdelrahman, Danielle M. Carlson, Ellen L. Larson, Erik Jessen, Dong-Gi Mun, Isaac Lynch, Alessandro Fogliati, Stella Konadu Adjei Antwi, Aushinie Abeynayake, Akhilesh Pandey, Mark J. Truty, Gregory J. Gores, Rory L. Smoot. Baseline multiomics and chemotherapy efficacy in preclinical trials using patient-derived xenograft models of cholangiocarcinoma can reveal distinct signatures of chemotherapy response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6762.
Abstract 7163: Noninvasive magnetic resonance imaging measured quantitative perfusion as predictive and prognostic biomarker in glioblastoma
Abstract Glioblastoma is highly vascularized with increased perfusion and prognosis remains dismal, despite improved diagnosis and aggressive multimodal treatment. The current standard of care is maximal surgical resection when feasible, followed by adjuvant radiation with concurrent chemotherapy, temozolomide. However, treatment resistance and tumor recurrence pose a considerable challenge for stratifying patients for optimal treatment planning. Current radiological assessment of glioblastoma therapy response predominantly relies on morphological measures; that may not accurately capture early microscopic changes or therapeutic efficacy. We have developed and validated an advanced imaging method, Arterial Spin Labeling (ASL) MRI that enable noninvasive spatial assessment of the entire tumor. ASL-MRI uses water within the blood as an endogenous tracer and measures perfusion without the need for exogenous gadolinium-based contrast agent. The objective of this study was to investigate ASL measured quantitative perfusion after surgery to predict survival in glioblastoma patients undergoing the standard of care chemoradiation treatment. In this prospective, IRB-approved study, twenty-three adults with glioblastoma participated for longitudinal MRI. Progression-free survival (PFS) and overall survival (OS) were recorded for each patient. A baseline MRI scan was performed prior to chemoradiation treatment and after surgery utilizing a 3D ASL sequence. All structural images were co-registered to T1 post-contrast images. Tumor regions of interest (ROIs) such as enhancing tumor (ET), tumor core, whole tumor, and necrosis were manually segmented. Cerebral blood flow maps were calculated and mean perfusion values (MPV) within ET ROIs were extracted. Scatter plot of MPV and Kaplan-Meier graphs were generated using GraphPad Prism. Based on median survival of 420 days, patients were categorized into short (≤420 days) or long (>420 days) survival. A threshold ASL measured perfusion value of 30 mL/100g/min distinguished survival groups; hyper-perfusion correlated with shorter OS, while hypo-perfusion linked to longer OS. The mean±SD of PFS and OS for patients with shorter survival were 119±42 days and 230±117 days respectively, while for longer survival were 624±285 and 726±210 days respectively, and the values were statistically different (P<0.001for both). Kaplan-Meier curves showed significant OS and PFS differences (p<0.015, Hazard Ratio=3.056). Our data indicate that ASL measured baseline perfusion, after surgery and before chemoradiation treatment can benefit in predicting survival and treatment stratification in glioblastoma patients. ASL measured perfusion can be performed during radiation treatment and could provide valuable information that can be incorporated into emerging treatment strategies such as adaptive radiation. Citation Format: Durga Udayakumar, Limin Zhou, Marco Pinho, Yiming Wang, Ben Wagner, Michael Youssef, Joseph Maldjian, Ananth Madhuranthakam. Noninvasive magnetic resonance imaging measured quantitative perfusion as predictive and prognostic biomarker in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7163.